BioSpace News Archive

A new report released today by the National Osteoporosis Foundation (NOF) finds that despite the existence of proven preventive measures, approximately 2 million Americans on Medicare suffered 2.3 million osteoporosis-related bone fractures in 2015.

Building on previous progress in the NIH Blueprint Neurotherapeutics program, AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM)

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options. Genprex has no affiliation with these researchers.

In only three minutes, rising-star researchers from high schoolers to post-doctoral investigators will highlight their research to more than 150 bioscience professionals, industry experts, enthusiasts, and judges at Oregon Bio 2019: Innovating and Scaling for our Region’s Growth.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that it has been added to the Russell 2000® and 3000® indexes effective September 20, 2019

Offering 18 independent living, 82 assisted living, and 22 memory care units, The Lodge at North Ogden is the fifth and final property in a portfolio acquisition completed by MedCore this year that consists of five properties with a total of 531 units.

Non-adherence to medications is an issue that puts the long-term health of millions of patients at risk.

This is a reminder that Sleep Better Austin at Hedgecock Dental is seeking to identify sleep apnea candidates for the Sleep Saves Lives event and will make eight free appliances for patients fitting the required profile for care.

The Austen Riggs Center (Riggs) announced the establishment of the “Four Freedoms of Mental Health Award.”

Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement (“Option”) with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor.